Mode
Text Size
Log in / Sign up
N/A N=45 Treatment

Clinical Investigation of the Nucleus® CI532 Cochlear Implant

Hearing Loss

Enrolled (actual)
45
Serious AEs
8.9%
Results posted
Nov 2018
Primary outcome: Primary: Scalar Position of Electrode Array Determined With Computer Tomography (CT) Scan — 44; 0 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Nucleus CI532 cochlear implant (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Cochlear
Primary completion
Jul 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Scalar Position of Electrode Array Determined With Computer Tomography (CT) Scan
44; 0
SECONDARY
Array Proximity to the Modiolus Measured Using the Wrapping Factor
0.62
SECONDARY
Surgeon Questionnaire on Implant Surgery
38
SECONDARY
Change From Baseline in Speech Recognition in Quiet and Noise at 6 Months
52.500; 29.668; 63.725; 33.690
SECONDARY
Patient Reported Benefit in Health Status Assessed Via Glasgow Benefit Inventory Questionnaire
28.1
SECONDARY
Change From Baseline in Hearing Ability Assessed Via Speech Spatial Hearing Qualities Questionnaire at 6 Months
2.22
SECONDARY
Change From Baseline in Air-conduction Pure-tone Hearing Thresholds Via an Audiogram at 6 Months
20
SECONDARY
Number of Adverse Events at Surgery
3
SECONDARY
Number of Adverse Events Post Surgery to 6 Months Post-activation
32

Summary

The aim of this study is to investigate the clinical benefit for patients implanted with the Nucleus® CI532 cochlear implant and to demonstrate the atraumatic nature of the electrode design. Nucleus® CI532 has a pre-curved, perimodiolar array, the EA32, which is introduced into the cochlea through a straightening sheath.

Eligibility Criteria

Inclusion Criteria

  • Eighteen years of age or older at the time of implantation
  • Conventional candidate for cochlear implantation with a perimodiolar electrode array according to local criteria (excepting the exclusion criteria that follow)
  • Native speaker in the local language used to assess clinical performance

Exclusion Criteria

  • Evidence of hearing loss prior to 5 years of age
  • Prior cochlear implantation; i.e. having a cochlear implant in the contralateral ear, or previously implanted in either ear
  • Medical or psychological conditions that contraindicate undergoing general anaesthesia or surgery
  • Ossification, malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, as confirmed by medical examination
  • Hearing impairment due to lesion or neuropathy of the acoustic nerve, VIII nerve or central auditory pathway
  • Active middle-ear infection
  • Tympanic membrane perforation
  • Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices
  • Unwillingness or inability of the candidate to comply with all investigational requirements such as undergoing a post-operative digital volume tomography/ConeBeam scan
  • Patients with existing Cerebral Spinal Fluid shunts or drains, existing perilymph fistula, skull fracture or Cerebral Spinal Fluid leak
  • Patients with recurrent episodes of bacterial meningitis
  • Pregnancy or breast-feeding
  • Known allergies to components of the implant
  • Wearing other active implants with known interference with cochlear implants
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02392403). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search